IndustryCompany release

Cypherpunk reports $306M Q3 net income as Leap starts sirexatamab partnering process

🇺🇸 Cypherpunk Technologies Inc. (CYPH) · Mon 16 Nov 2026

The Nasdaq-listed Zcash treasury company says a non-cash derivative gain drove its profit, while its Leap Therapeutics unit seeks funding or a partner for a colorectal cancer candidate.

Cypherpunk Technologies, formerly known as Leap Therapeutics, reported third-quarter 2026 results on 16 November 2026. The Nasdaq-listed company holds a Zcash treasury and retains Leap Therapeutics as a subsidiary.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Cypherpunk Technologies Inc. ↗

Article written by VigiEye from the official source (Cypherpunk Technologies Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →